ClinicalTrials.gg

Program

roluperidone

Also written as “MIN-101”, “Roluperidone 64 mg” and “Roluperidone”.

Its studies are mostly in Schizophrenia, led by 2 companies.

Furthest: phase 3, since Dec 29, 20177 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minerva Neurosciences61 open or runningphase 3since Dec 29, 2017Sep 3, 2014Dec 2027phase 3 · NCT07565428
Cyrenaic Pharmaceuticals10 open or runningphase 2since Mar 11, 2009Mar 11, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2009First study: phase 2 study in SchizophreniaNew to Cyrenaic PharmaceuticalsCyrenaic Pharmaceuticals · NCT00861796 · 100 enrolled · France
  2. Sep 3, 2014Minerva Neurosciences's first study: phase 1 study in SchizophreniaNew to Minerva NeurosciencesMinerva Neurosciences · NCT02232529 · 32 enrolled · United Kingdom
  3. Jan 10, 2017Phase 1 study in Healthy SubjectsMinerva Neurosciences · NCT03038646 · 14 enrolled · Ireland
  4. Feb 23, 2017Phase 1 study in Healthy SubjectsMinerva Neurosciences · NCT03072056 · 23 enrolled · Ireland
  5. Dec 29, 2017Phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT03397134 · 515 enrolled · United States, Bulgaria, Poland and more
  6. Oct 13, 2023Phase 1 study in Negative Symptoms in SchizophreniaMinerva Neurosciences · NCT06107803 · 17 enrolled · United States
  7. Apr 21, 2026Phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT07565428 · 380 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT07565428

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07565428Negative Symptoms of Schizophrenia · United States3RecruitingMinerva NeurosciencesDec 2027380
NCT06107803Negative Symptoms in Schizophrenia · United States1CompletedMinerva NeurosciencesJan 12, 202417
NCT03397134Negative Symptoms of Schizophrenia · United States, Bulgaria, Poland and more3CompletedMinerva NeurosciencesMay 26, 2020515
NCT03072056Healthy Subjects · Ireland1CompletedMinerva NeurosciencesJul 7, 201723
NCT03038646Healthy Subjects · Ireland1CompletedMinerva NeurosciencesApr 20, 201714
NCT02232529Schizophrenia · United Kingdom1CompletedMinerva NeurosciencesFeb 201532
NCT00861796Schizophrenia · France2CompletedCyrenaic PharmaceuticalsMay 2010100

How it is read

Names in the registry

  • “MIN-101”, 3 entries
  • “Roluperidone 64 mg”, 2 entries
  • “Roluperidone”, 1 entry
  • “Roluperidone 32 mg”, 1 entry
  • “CYR-101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.